このエントリーをはてなブックマークに追加
ID 30705
JaLCDOI
フルテキストURL
著者
Takahashi, Isao Okayama University
Hara, Masamichi Okayama University
Uchida, Kozaburo Okayama University
Takaoka, Kazuko Okayama University
Watanabe, Seiichiro Okayama University
Lai, Minyu Okayama University
Hamasaki, Kazuhide Okayama University
Kohi, Fumikazu Okayama University
Kitajima, Koichi Okayama University
Kimura, Ikuro Okayama University
Adachi, Tomiro Okayama City Hospital
Yorimitsu, Seiichi Ehime Central Hospital
Tokioka, Masaaki Okayama National Hospital
Sanada, Hiroshi Okayama University
抄録

Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.

キーワード
aclarubicin
cytosine arabinoside
chemotherapy
acute myelocytic leukemia
Amo Type
Brief Note
発行日
1982-02
出版物タイトル
Acta Medica Okayama
36巻
1号
出版者
Okayama University Medical School
開始ページ
77
終了ページ
80
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT